Imaging and Tracer platform provides facilities for the development of new therapies such as target therapy, stem cell imaging & tracking etc. it aims to identify and validate new prognostic and predictive imaging-based markers of therapy response.

MAIN INFRASTRUCTURES AND METHODOLOGIES AVAILABLE

The platform provides advanced technologies in preclinical and clinical field for the study and the development of disease specific tracers, contrast agents and radiolabeled drugs. It has competence in preclinical and clinical research and it also participates in clinical trials.

The competence areas of platform are neurodegenerative disorders, cardiovascular diseases, psychiatric diseases, diseases of the musculoskeletal system, inflammation, oncology, transplant, orthopedics, pharmacology.

The imaging and tracing platform interacts with other product platforms.

Preclinical methodologies:

• Bioluminescence
• Fluorescence
• Micro CT
• MRI/MRS (4.7 & 9.4 tesla)
• Pet
• US

 Clinical methodologies:

• CT
• CT spectral imaging
• MRI
• fMRI
• Tractography
• MRS
• MRI/CT
• PET
• PET/SPECT/CT
• PET/CT
• PET/MRI
• US

TASK FORCE

Chair: Dr. Rossella Canese (ISS)
Co-Chair: Dr. Alberto Bazzocchi; Dr. Paola Spessotto